The effects of bufadienolides on HER2 overexpressing breast cancer cells

被引：10
|
作者：
Wang, Tianjiao [1 ]
Mu, Lin [2 ]
Jin, Haifeng [1 ]
Zhang, Peng [1 ]
Wang, Yueyue [1 ]
Ma, Xiaochi [2 ]
Pan, Jinjin [1 ]
Miao, Jian [3 ]
Yuan, Yuhui [1 ]
机构：
[1] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian, Peoples R China
[2] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China
[3] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China
来源：
TUMOR BIOLOGY | 2016年 / 37卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Breast cancer; HER2; SRC-1; SRC-3; GROWTH-FACTOR-RECEPTOR; TAMOXIFEN RESISTANCE; TOAD VENOM; COACTIVATOR AIB1; ESTROGEN; ARENOBUFAGIN; SRC-3; PROLIFERATION; TRANSCRIPTION; MECHANISMS;
D O I：
10.1007/s13277-015-4381-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2 is a proto-oncogene frequently amplified in human breast cancer, its overexpression is correlated with tamoxifen resistance and decreased recurrence-free survival. Arenobufagin and bufalin are homogeneous bufadienolides of cardiac glycosides agents. In this research, we studied the effects of arenobufagin and bufalin on cellular survival and proliferation of HER2 overexpressing breast cancer cells and the mechanism under the results including the direct effect on HER2 downstream pathways. Our results showed that arenobufagin and bufalin could significantly inhibit the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-1, SRC-3, nuclear transcription factor E2F1, phosphorylated AKT, and ERK. And the combination of each bufadienolide in low dose with tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpressing breast cancer cells. All above suggest that arenobufagin and bufalin may be potential therapy adjuvants for HER2 overexpressing breast cancer therapy.
引用
收藏
页码：7155 / 7163
页数：9
相关论文
共 50 条
  • [21] Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate
    Zhang, DY
    Li, Y
    Rizvi, SMA
    Qu, CF
    Kearsley, J
    Allen, BJ
    CANCER LETTERS, 2005, 218 (02) : 181 - 190
  • [22] Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
    Taskar, Kunal S.
    Rudraraju, Vinay
    Mittapalli, Rajendar K.
    Samala, Ramakrishna
    Thorsheim, Helen R.
    Lockman, Julie
    Gril, Brunilde
    Hua, Emily
    Palmieri, Diane
    Polli, Joseph W.
    Castellino, Stephen
    Rubin, Stephen D.
    Lockman, Paul R.
    Steeg, Patricia S.
    Smith, Quentin R.
    PHARMACEUTICAL RESEARCH, 2012, 29 (03) : 770 - 781
  • [23] Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
    Kunal S. Taskar
    Vinay Rudraraju
    Rajendar K. Mittapalli
    Ramakrishna Samala
    Helen R. Thorsheim
    Julie Lockman
    Brunilde Gril
    Emily Hua
    Diane Palmieri
    Joseph W. Polli
    Stephen Castellino
    Stephen D. Rubin
    Paul R. Lockman
    Patricia S. Steeg
    Quentin R. Smith
    Pharmaceutical Research, 2012, 29 : 770 - 781
  • [24] A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
    Angeli, Eurydice
    Paris, Justine
    Le Tilly, Olivier
    Desvignes, Celine
    Gapihan, Guillaume
    Boquet, Didier
    Pamoukdjian, Frederic
    Hamdan, Diaddin
    Rigal, Marthe
    Poirier, Florence
    Lutomski, Didier
    Azibani, Feriel
    Mebazaa, Alexandre
    Herbet, Amaury
    Mabondzo, Aloise
    Falgarone, Geraldine
    Janin, Anne
    Paintaud, Gilles
    Bousquet, Guilhem
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [25] A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
    Menyhart, Otilia
    Santarpia, Libero
    Gyorffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2015, 15 (08) : 665 - 683
  • [26] Inhibitory effects of calcitriol and the vitamin D analogue paricalcitol in combination with chemotherapy on the growth of HER2 overexpressing breast cancer cells
    Mateos-Soria, A. S.
    Garcia-Becerra, R. A.
    Diaz-Nieto, L.
    Ventura-Gallegos, J. L.
    Jacobo-Herrera, N.
    Soto-Perez-de-Celis, E.
    Zentella-Dehesa, A.
    Chavarri-Guera, Y.
    CANCER RESEARCH, 2016, 76
  • [27] CHARACTERIZATION OF SIGNALING PATHWAYS IN HER2/NEU OVEREXPRESSING BREAST TUMORS. INCREASE IN AKT 1/PROTEIN KINASE B LEADS TO HERCEPTIN RESISTANCE IN HER2/NEU OVEREXPRESSING BREAST CANCER CELLS
    Vadgama, J.
    Wu, Y.
    Okafar, A.
    Sakurai, R.
    Thant, A.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3661 - 3662
  • [28] Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells
    Ma, Chuandong
    Niu, Xiuqing
    Luo, Jianmin
    Shao, Zhimin
    Shen, Kunwei
    CANCER SCIENCE, 2010, 101 (10) : 2220 - 2226
  • [29] Modeling HER2 Inhibition in Breast Cancer Cells
    Fink, Marc Y.
    Zhou, Danni
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 614A - 614A
  • [30] Pomolic acid inhibits metastasis of HER2 overexpressing breast cancer cells through inactivation of the ERK pathway
    Kim, Buyun
    Kim, Yu Chul
    Park, Byoungduck
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (02) : 744 - 752
12345